These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 3509070)
1. Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Berrettini WH; Doran AR; Kelsoe J; Roy A; Pickar D Neuropsychopharmacology; 1987 Dec; 1(1):81-3. PubMed ID: 3509070 [TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. Widerlöv E; Lindström LH; Wahlestedt C; Ekman R J Psychiatr Res; 1988; 22(1):69-79. PubMed ID: 3397912 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. Gjerris A; Widerlöv E; Werdelin L; Ekman R J Psychiatry Neurosci; 1992 Mar; 17(1):23-7. PubMed ID: 1349825 [TBL] [Abstract][Full Text] [Related]
4. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Nikisch G; Baumann P; Liu T; Mathé AA Int J Neuropsychopharmacol; 2012 Sep; 15(8):1051-61. PubMed ID: 22008251 [TBL] [Abstract][Full Text] [Related]
5. CSF neuropeptide Y in alcoholics and normal controls. Roy A; Berrettini W; DeJong J; Adinoff B; Ravitz B; Linnoila M Psychiatry Res; 1990 Sep; 33(3):215-9. PubMed ID: 1978753 [TBL] [Abstract][Full Text] [Related]
6. Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers. Lindström LH; Ekman R; Walleus H; Widerlöv E Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(1):83-90. PubMed ID: 2859636 [TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Peters J; Van Kammen DP; Gelernter J; Yao J; Shaw D Schizophr Res; 1990; 3(5-6):287-94. PubMed ID: 2178001 [TBL] [Abstract][Full Text] [Related]
9. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. Heilig M; Zachrisson O; Thorsell A; Ehnvall A; Mottagui-Tabar S; Sjögren M; Asberg M; Ekman R; Wahlestedt C; Agren H J Psychiatr Res; 2004; 38(2):113-21. PubMed ID: 14757324 [TBL] [Abstract][Full Text] [Related]
10. Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. Barbaccia ML; Costa E; Ferrero P; Guidotti A; Roy A; Sunderland T; Pickar D; Paul SM; Goodwin FK Arch Gen Psychiatry; 1986 Dec; 43(12):1143-7. PubMed ID: 3022663 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid neuropeptide Y levels in major depression and reported childhood trauma. Soleimani L; Oquendo MA; Sullivan GM; Mathé AA; Mann JJ Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539507 [TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y levels in central and peripheral cerebrospinal fluid in patients with intracranial disorders. von Holst H; Rudehill A; Lundberg JM Acta Neurochir (Wien); 1991; 112(3-4):132-5. PubMed ID: 1776515 [TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y immunoreactivity in human cerebrospinal fluid. Berrettini WH; Nurnberger JI; DiMaggio DA Peptides; 1986; 7(3):455-8. PubMed ID: 3774588 [TBL] [Abstract][Full Text] [Related]
15. Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders. Bissette G; Widerlöv E; Walléus H; Karlsson I; Eklund K; Forsman A; Nemeroff CB Arch Gen Psychiatry; 1986 Dec; 43(12):1148-51. PubMed ID: 3778111 [TBL] [Abstract][Full Text] [Related]
16. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Hou C; Jia F; Liu Y; Li L Brain Res; 2006 Jun; 1095(1):154-8. PubMed ID: 16713589 [TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y, social function and long-term outcome in schizophrenia. Stålberg G; Ekselius L; Lindström LH; Larhammar D; Bodén R Schizophr Res; 2014 Jul; 156(2-3):223-7. PubMed ID: 24799298 [TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment. Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395 [TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y - an early biomarker for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Schebesch KM; Brawanski A; Bele S; Schödel P; Herbst A; Bründl E; Kagerbauer SM; Martin J; Lohmeier A; Stoerr EM; Proescholdt M Neurol Res; 2013 Dec; 35(10):1038-43. PubMed ID: 23915659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]